- Home
- OPT vs GSL Comparison
OPT vs GSL Comparison
Compare OPT & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- GSL
- Stock Information
- Founded
- OPT 1984
- GSL 2007
- Country
- OPT Australia
- GSL Greece
- Employees
- OPT N/A
- GSL N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- GSL Marine Transportation
- Sector
- OPT Health Care
- GSL Consumer Discretionary
- Exchange
- OPT Nasdaq
- GSL Nasdaq
- Market Cap
- OPT 767.9M
- GSL 877.6M
- IPO Year
- OPT 2020
- GSL 2006
- Fundamental
- Price
- OPT $3.24
- GSL $23.65
- Analyst Decision
- OPT Strong Buy
- GSL Strong Buy
- Analyst Count
- OPT 1
- GSL 1
- Target Price
- OPT $12.00
- GSL $29.00
- AVG Volume (30 Days)
- OPT 39.0K
- GSL 376.7K
- Earning Date
- OPT 08-30-2024
- GSL 11-11-2024
- Dividend Yield
- OPT N/A
- GSL 6.66%
- EPS Growth
- OPT N/A
- GSL 7.25
- EPS
- OPT N/A
- GSL 8.99
- Revenue
- OPT $261,859.00
- GSL $701,476,000.00
- Revenue This Year
- OPT N/A
- GSL $7.05
- Revenue Next Year
- OPT $46,864.64
- GSL N/A
- P/E Ratio
- OPT N/A
- GSL $2.63
- Revenue Growth
- OPT N/A
- GSL 8.60
- 52 Week Low
- OPT $1.79
- GSL $17.47
- 52 Week High
- OPT $5.45
- GSL $30.32
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- GSL 43.85
- Support Level
- OPT $4.02
- GSL $23.03
- Resistance Level
- OPT $4.18
- GSL $24.54
- Average True Range (ATR)
- OPT 0.22
- GSL 0.71
- MACD
- OPT -0.13
- GSL 0.00
- Stochastic Oscillator
- OPT 6.85
- GSL 31.99
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.